Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.40 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 7/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357835 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2HTR2CSLC6A2 | |
| SCHEMBL1005903 | 0.90 | NOS1 (0.41) | NOS1NOS3NOS2HTR2CHTR1A | |
| SCHEMBL29941060 | 0.73 | JAK2 (0.37) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL9559207 | 0.73 | NOS1 (0.47) | NOS1NOS3NOS2HTR1AADRA1A | |
| SCHEMBL30074503 | 0.71 | NOS1 (0.50) | NOS1NOS3NOS2HTR1AADRA1A | |
| SCHEMBL145755 | 0.71 | NOS1 (0.50) | NOS1NOS3NOS2HTR1AADRA1A | |
| SCHEMBL6004098 | 0.70 | NOS1 (0.36) | NOS1NOS3NOS2HTR1AADRA1A | |
| SCHEMBL3272037 | 0.69 | KDM4E (0.35) | NOS1NOS3NOS2 | |
| SCHEMBL16115899 | 0.69 | NOS1 (0.44) | NOS1NOS3NOS2SIGMAR1 | |
| SCHEMBL3922142 | 0.69 | NOS1 (0.40) | NOS1NOS3NOS2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023130070-A2 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | claimed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | OLEMA PHARMACEUTICALS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2024-03-14 | — | — | US | disclosed |
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | disclosed |
| CN-112351984-B | Tetrahydrobenzofuro [2.3-c ] pyridine and beta-carboline compounds for the treatment, alleviation or prevention of conditions associated with Tau aggregate | AC免疫有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA, INC (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004071445-A2 | 2-(AMINOMETHYL)ARYLAMIDE ANALGESICS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| EP-1360186-A2 | CARBOLINE DERIVATIVES | Lilly Icos LLC (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1350112-A2 | METHODS FOR THE TREATMENT OF IBS | Pharmagene Laboratories Ltd (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002064591-A2 | CARBOLINE DERIVATIVES | LILLY ICOS LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002056010-A2 | METHODS FOR THE TREATMENT OF IBS | PHARMAGENE LABORATORIES LTD (GB) | 2002-07-18 | — | — | WO | disclosed |
| US-4719211-A | PSYCHOLOGIAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0021857-A1 | Indole derivatives, their preparation and therapeutical compositions containing them | SYNTHELABO (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | NOS1 250/4885NOS3 401/4885NOS2 309/4885 |
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | MAOB, TPSG1, TPSB2 | NOS1 89/4885NOS3 106/4885NOS2 105/4885 |
| US-20240131013-A1 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | NOS1 1059/4885NOS3 547/4885NOS2 1482/4885 |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | NOS1 4410/4885NOS3 4004/4885NOS2 4218/4885 |
| US-20040167119-A1 | 2-(aminomethyl) arylamide analgesics | OPRL1, OPRM1, OPRK1 | NOS1 3346/4885NOS3 2799/4885NOS2 1947/4885 |
| US-20240226073-A9 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | ESR1, CYP19A1, HSD17B11 | NOS1 1059/4885NOS3 547/4885NOS2 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.